Azilsartan Suppresses Osteoclastogenesis and Ameliorates Ovariectomy-Induced Osteoporosis by Inhibiting Reactive Oxygen Species Production and Activating Nrf2 Signaling

Bin Pan¹,²,³, Lin Zheng¹,², Jiawei Fang¹,³, Ye Lin¹,³, Hehuan Lai³, Jiawei Gao¹,²,³, Wenzheng Pan¹,³, Yejin Zhang¹,²,³, Kainan Ni¹,³, Chao Lou¹,³* and Dengwei He¹,³*

¹Department of Orthopedics, Lishui hospital, Zhejiang University School of Medicine, Lishui, China, ²Department of Orthopedic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, ³Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research of Zhejiang Province, Lishui hospital, Lishui, China.

Osteoporosis is characterized by a decrease in bone mass and destruction of the bone microarchitecture, and it commonly occurs in postmenopausal women and the elderly. Overactivation of osteoclasts caused by the inflammatory response or oxidative stress leads to osteoporosis. An increasing number of studies have suggested that intracellular reactive oxygen species (ROS) are strongly associated with osteoclastogenesis. As a novel angiotensin (Ang) II receptor blocker (ARB), azilsartan was reported to be associated with the inhibition of intracellular oxidative stress processes. However, the relationship between azilsartan and osteoclastogenesis is still unknown. In this study, we explored the effect of azilsartan on ovariectomy-induced osteoporosis in mice. Azilsartan significantly inhibited the receptor activator of nuclear factor-κB ligand (RANKL)-mediated osteoclastogenesis and downregulated the expression of osteoclast-associated markers (Nfatc1, c-Fos, and Ctsk) in vitro. Furthermore, azilsartan reduced RANKL-induced ROS production by increasing the expression of nuclear factor erythroid 2-related factor 2 (Nrf2). Mechanistically, azilsartan inhibited the activation of MAPK/NF-κB signaling pathways, while Nrf2 silencing reversed the inhibitory effect of azilsartan on MAPK/NF-κB signaling pathways. Consistent with the in vitro data, azilsartan administration ameliorated ovariectomy (OVX)-induced osteoporosis, and decreased ROS levels in vivo. In conclusion, azilsartan inhibited oxidative stress and may be a novel treatment strategy for osteoporosis caused by osteoclast overactivation.

Keywords: osteoporosis, reactive oxygen species, Nrf2, osteoclast, azilsartan
INTRODUCTION

Bone homeostasis is mainly sustained by the synergistic actions of two types of cells, namely, osteoblasts for osteogenesis and osteoclasts for osteolysis (Rodan and Martin, 2000; Raisz, 2005). Osteoclasts have been reported to function in promoting bone resorption and maintaining bone homeostasis (Clézardin et al., 2021). However, various pathological conditions may contribute to osteoclast overactivation, including estrogen deficiency in postmenopausal women, inflammation, and oxidative stress (Rodan and Martin, 2000; Manolagas, 2010; Manolagas et al., 2013).

Osteoclasts are identified as multinucleated cells that originate from the monocyte/macrophage lineage and are modulated by receptor activator of nuclear factor-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) (Bruzzi and Baron, 2006; Honma et al., 2021). By recruiting TRAF6, RANK further mobilizes the mitogen-activated protein kinases (MAPKs) and nuclear factor (NF)-κB signaling pathways (Walsh et al., 2015), which are critical signals that trigger the transcriptional activity of nuclear factor of activated T cells 1 (NFATc1) and c-Fos in osteoclastogenesis (Boyle et al., 2003; Yamashita et al., 2007; Boutros et al., 2008; Novack, 2011; Tan et al., 2017).

Reactive oxygen species (ROS) are also engaged in bone metabolism (Lean et al., 2003; Sasaki et al., 2009). Upon RANKL stimulation, osteoclast precursors produce endogenous ROS via RANK, TRAF6, Rac1, and Nox1 cascades (Lee et al., 2005). Several studies have confirmed that the inhibition of ROS production prevents osteoclastogenesis (Lee et al., 2005; Chen et al., 2019). Nrf2 is a redox-sensitive leucine zipper transcription factor that decreases ROS levels by promoting the transcription of antioxidant enzymes (Ishii et al., 2000), including glutathione S-transferases (GSTs), heme oxygenase-1 (HO-1), superoxide dismutase (SOD) 1, NAD(P)H:quinone oxidoreductase (NQO) 1, and Catalase (Nioi et al., 2003; Sun et al., 2015). Nrf2 deficiency resulted in increased intracellular ROS levels, defective antioxidant enzyme transcription, and significantly increased osteoclast formation (Hyeon et al., 2013).

Angiotensin (Ang) II, an octapeptide component of the renin-angiotensin system (RAS), exerts its effects through two pharmacologically different G protein-coupled receptors: AT1R and AT2R (de Cavanagh et al., 2004; Benigni et al., 2010). Previous studies have documented the local expression of AT1R in the skeletal system of humans and animals (Zhang et al., 2019). Several components of the RAS, such as AT1R, AT2R, and ACE, are upregulated in mouse calvarial tissue during titanium-induced osteolysis (Zhao et al., 2021). In addition, Yutaro et al. reported that AT1R was existing in osteoblasts, BMMs, preosteoclasts and mature osteoclasts (Asaba et al., 2009). According to recent studies, angiotensin II (Ang II) is involved in bone metabolism and oxidative stress by binding to the AT1 receptor. Deletion of AT1aR increases the number and volume of bone trabeculae and attenuates oxidative stress (Benigni et al., 2009; Kaneko et al., 2011).

Azilsartan, a blocker of the AT1R receptor (ARB), has been approved for clinical use, and it inhibits AT1R-mediated biological effects. Azilsartan restores endothelial function in the inflammatory response by suppressing inflammation and increasing e-NOS phosphorylation (Matsumoto et al., 2014; Liu et al., 2016; Lei et al., 2021). Meanwhile, azilsartan inhibits LPS-induced inflammatory responses in macrophages by suppressing oxidative stress (Dong et al., 2021). However, the effect of azilsartan on osteoclastogenesis has not been evaluated.

In our study, we found that azilsartan inhibited osteoclast formation and resorption function in vitro and ameliorated osteoporosis in ovariectomy (OVX) mice. We firstly find that azilsartan may be a promising drug candidate in the treatment for skeletal disorders associated with osteoclasts.

MATERIALS AND METHODS

Animal Ethics

Six to eight-week-old C57BL/6J mice were purchased from Shanghai Silaie Experimental Animals Center. All mice were housed in cages with ventilation filters under natural light and were provided food and water without any restrictions. The temperature in the room was maintained at 23°C. All animal experiments were approved by the Ethics Committee of Lishui Hospital (Zhejiang University, Zhejiang, China) and were conducted according to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, China).

Reagents and Antibodies

Azilsartan was obtained from Selleck Chemicals (Selleck Chemicals, Houston, TX, United States). Azilsartan was dissolved in DMSO (Sigma–Aldrich, Sydney, Australia) and stored at −20°C until use. Fetal bovine serum (FBS) and α-MEM were purchased from Gibco (Gaithersburg, MD, United States). Recombinant M-CSF and RANKL were purchased from R&D Systems (Minneapolis, MN, United States). Specific antibodies against c-Fos, CTSK, NFATc1, GAPDH, p-β-actin and HO-1 were purchased from Abcam (Cambridge, United Kingdom). Antibodies against p-JNK, JNK, p-ERK, ERK, p-P65, P65, and Nrf2 were purchased from Cell Signaling Technology (Danvers, MA, United States). Cell Counting Kit-8 (CCK-8) was purchased from Solarbio Science and Technology (Solarbio, Beijing, China).

Mouse Bone Marrow-Derived Monocytes/ Macrophages Isolation and Culture in vitro

We isolated bone marrow-derived monocytes/macrophages (BMMs) from bone marrow flushes of mouse lower limb long bones using a previously published protocol (Zhao et al., 2019). The BMMs were cultured in complete α-MEM containing 10% FBS, 25 ng/mL M-CSF, and 100 U/ml penicillin-streptomycin. After 4–5 days in culture, the BMMs were collected for experimental purpose.
Cytotoxicity Assay
Cell proliferation and cytotoxicity were assessed using CCK-8 assays according to the manufacturer’s protocol. Briefly, \(2 \times 10^4\) BMMs were seeded on the surface of 96-well plates, cultured in \(\alpha\)-MEM for 24 h, and then treated with various concentrations of azilsartan. At 48 h and 96 h, the medium was replaced with 10 µL of CCK-8 reagent and 90 µL of complete \(\alpha\)-MEM for 2 h in a 37°C incubator. Then, the optical density value of each well was measured at 450 nm.

TRAP Staining and Bone Pit Assay
We tested the effect of azilsartan on osteoclastogenesis and bone resorption function by performing TRAP staining and bone pit formation assays. Briefly, \(1 \times 10^5\) BMMs were seeded into 24-well plates and cultured with \(\alpha\)-MEM containing M-CSF for 48 h. Then, different concentrations (0, 0.25, 0.5, or 1 µM) of azilsartan were added to the complete \(\alpha\)-MEM containing RANKL (100 ng/ml) and M-CSF for the indicated periods, and the complete medium was replaced every 2 days. At last, cells were flushed 3 times with phosphate-buffered saline (PBS) and then fixed with 4% paraformaldehyde (PFA) for 20 min at room temperature. Finally, these cells were prepared for TRAP staining. TRAP-positive multinucleated cells with ≥3–5 nuclei were identified as mature osteoclasts.

The bone resorption function of osteoclasts was assessed by bone pit assay. \(1 \times 10^5\) BMMs were seeded on collagen-coated 6-well plates (Corning, Inc., NY, United States) first and then stimulated with M-CSF (25 ng/ml) and RANKL (100 ng/ml) until small osteoclasts formed. Small osteoclasts were released gently from collagen-coated 6-well plates using the cell dissociation solution (Sigma, MO, United States) and reseeded in equal numbers on Corning hydroxyapatite-coated plates (Corning Inc., NY, United States). Small osteoclasts were cultured in complete \(\alpha\)-MEM containing RANKL (100 ng/ml) and different concentrations (0, 0.25, 0.5, or 1 µM) of azilsartan for 2–3 days to observe osteoclast-mediated bone resorption.

Finally, the plates were soaked 3 times with phosphate-buffered saline (PBS) and then fixed with 5% sodium hypochlorite solution for 2 min followed by washes with purified water until all cells were removed from plate. The bone resorption areas were photographed using Olympus light microscope (Olympus Life Science, Tokyo, Japan). Quantitative analysis was performed by ImageJ software (NIH; Bethesda, MD, United States).

Total RNA Isolation and qRT–PCR Analysis
Briefly, BMMs were seeded in 12-well plates (\(2 \times 10^5\) cells per well) and cultured in \(\alpha\)-MEM containing M-CSF (25 ng/ml), RANKL (100 ng/ml) and different concentrations of azilsartan for 5 days. Total cellular RNA was extracted from osteoclasts using an Ultrapure RNA Kit (CWBIO Inc., Beijing, China) in accordance with the protocol. Next, 1 µg of total mRNA was reverse transcribed to cDNAs using a HiFiScript cDNA synthesis kit (CWBIO Inc., Beijing, China). Real-time quantitative PCR was performed using SYBR Green qPCR Master Mix (Yeasen, Shanghai, China) and an ABI 7500 machine (Thermo Fisher Scientific). Relative gene expression was normalized to the expression of \(\beta\)-actin or GAPDH using the \(2^{-\Delta\Delta Ct}\) method. All primer sequences are listed in Supplementary Table S1.

Cell Transfection
Small interfering RNAs (siRNAs) that specifically target mouse Nrf2 gene were designed by RiboBio (RiboBio, Guangzhou, China). The siNrf2 sequences are listed in Supplementary Table S1. SiNrf2 were transfected into BMMs using Lipofectamine 3,000 (Invitrogen, CA, United States) in accordance with the manufacturer’s instructions. Briefly, \(5 \times 10^4\) BMMs were seeded in each well of 24-well plates the day before transfection. After 48 h of incubation, BMMs were transfected with 20 nM siRNA. After 6 h, the medium containing transfection reagent was replaced with complete \(\alpha\)-MEM containing M-CSF and RANKL (100 ng/ml). Forty-eight hours later, total mRNA was extracted for quantitative PCR analysis; 72 h later, total proteins were collected for Western blot analysis.

Western Blot Analysis
Total cellular protein was extracted from osteoclasts using RIPA buffer (CWBIO Inc., Beijing, China) containing PMSF (1%). Ten micrograms of total protein were separated on SDS–PAGE gels and transferred to PVDF membranes (Bio–Rad, Hercules, United States). Then, the membranes were blocked with milk (5%) in TBST for 1 h and incubated with the primary antibody (1:1,000) with shaking overnight at 4°C. After 16 h of incubation, the membranes were rinsed with Tris-Buffered Saline containing Tween-20 (TBST) for 3 times and incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at room temperature. Antibody activities were detected with enhanced ECL hypersensitive chemical luminescence reagents (Yeasen, Shanghai, China). Images were acquired using an Invitrogen iBright 1,500 instrument (Thermo Fisher Scientific) and analyzed using ImageJ software.

Intracellular Reactive Oxygen Species Detection
Intracellular and intramitochondrial ROS activity were measured using a DCFH-DA probe (Yeasen, Shanghai, China) and a MitoSOX Red assay kit (Yeasen, Shanghai, China). Briefly, BMMs were stimulated with or without RANKL and cultured with different concentrations (0, 0.5, or 1 µM) of azilsartan for 24 h. Then, the probe (5 µM) was added to each well and incubated at 37°C for 20 min. Next, the wells were washed 3 times with cold PBS, and the fluorescence was observed with the fluorescence microscope (Olympus Life Science, Tokyo, Japan). The fluorescence intensity was measured by ImageJ Software.

Mouse OVX-Induced Osteoporosis Model
A mouse ovariectomy (OVX)-induced osteoporosis model was adopted to evaluate the effect of azilsartan in vivo. Ten weeks old mice were randomly divided into 4 groups (\(n = 6\) mice per group): sham group (ovaries were only exteriorized but not resected), vehicle group (bilateral ovariectomy + normal saline gavage),
low-dose group (bilateral ovariectomy +1 mg/kg azilsartan gavage) and high-dose group (bilateral ovariectomy + 3 mg/kg azilsartan gavage). The dose of azilsartan used was based on the previous study (AbdelSaid et al., 2014; Sukumaran et al., 2017). All mice were anaesthetized by administering an intraperitoneal injection of pentobarbital (40 mg/kg body weight). Mice with a uniform heartbeat and respiration, relaxed muscles, no movement of limbs and, no touching reaction of whiskers were considered to have reached the state of complete anesthesia. The surgical procedure was performed as previously described (Xu et al., 2021). Azilsartan was administered by oral gavage twice a week for 6 weeks beginning on the seventh postoperative day. All mice were euthanized under anesthesia after 6 weeks of azilsartan intervention. The serum sample was collected from each mouse for liver functional enzyme analysis before the mice were euthanized. Then, all femurs and tibias of mice were harvested for the following experiments.

μCT and Image Reconstruction
After fixation with 4% PFA for 48 h, the mouse right tibia and femur were scanned using a SkyScan 1,275 micro-CT (Bruker, Billerica, MA, United States). Data were analyzed using the following conditions: 50 kV, 9 µm resolution and 75 µA. All images were reconstructed with SkyScan CTAn software. The quantitative analysis was performed within a region set at 150 layers below the growth plate. Related parameters, including trabecular thickness (Tb. Th), bone volume per tissue volume (BV/TV), trabecular number (Tb. N), and trabecular separation (Tb. Sp), were recorded and analyzed.

Bone Histomorphometric Analysis
All tibias were decalcified in 10% ethylenediaminetetraacetic acid (EDTA) (Sigma, Australia) at 4°C for 14 days. Tibias were dehydrated, embedded in paraffin blocks, and sectioned using a microtome at a thickness of 5 µm. Then, the bone sections were subjected to hematoxylin and eosin (H&E) and TRAP staining. The number of TRAP-positive osteoclast and osteoclast surfaces subjected to hematoxylin and eosin (H&E) and TRAP staining. Brie

RESULTS
Azilsartan Inhibits RANKL-Induced Osteoclastogenesis in vitro
The chemical structure of azilsartan is shown in Figure 1A. We performed CCK-8 cell proliferation and cytotoxicity assays in 96-well plates after BMMs were treated with various concentrations of azilsartan to detect the cytotoxicity of azilsartan toward BMMs. As shown in Figure 1B, azilsartan had no effect on cell viability at concentrations ranging from 0 to 1 µM (48 h and 96 h). Next, TRAP staining results showed the formation of a large number of TRAP-positive multinucleated osteoclasts in the control group (0 µM), while osteoclastogenesis was inhibited in a dose-dependent manner by increasing concentrations of azilsartan (Figures 1C,D).

We treated BMMs with 0.5 µM azilsartan at different times to explore which stage of osteoclastogenesis was affected. Interestingly, osteoclast formation was more significantly inhibited when azilsartan was added at the mid-late stage (Days 3–5), while the inhibitory effect was not apparent at the early stage (Days 1–3) (Figures 1E,F).

Azilsartan Affects Osteoclast Resorption Function and Suppresses Osteoclast-Specific Gene Expression
We next tested whether azilsartan affected osteoclast bone resorption function. Mature small osteoclasts were reseeded on the surface of Corning hydroxyapatite-coated plates and treated with different concentrations of azilsartan (0, 0.25, 0.5, or 1 µM) for 3 days. As shown in Figure 2A, azilsartan treatment significantly reduced the bone resorption area in a dose-dependent manner compared with that of the untreated control group (Figure 2B).

Several osteoclast markers, including Cathepsin K (CTSK), Tartrate Resistant Acid Phosphatase (TRAP), Dendritic Cell-Specific Transmembrane Protein (DC-STAMP), D2 isoform of vacuolar ATPase Vo domain (ATP6v0d2), NFATc1, and c-Fos are upregulated during RANKL-induced osteoclastogenesis (Zheng et al., 2019; Yang et al., 2021). Our results revealed that azilsartan significantly suppressed the expression of these genes compared with the untreated control group (Figure 2C).

Next, we investigated the expression levels of proteins associated with osteoclastogenesis and osteolysis, namely, NFATc1 and CTSK, using Western blot analysis. Consistent with the quantitative PCR results, different concentrations of azilsartan exerted an inhibitory effect on osteoclastogenesis and bone resorption, but were not toxicity effect of azilsartan (Figures 2D,E).

Azilsartan Inhibits the RANKL-Induced Activation of the NF-κB and MAPK Pathways
We identified the molecular mechanisms by which azilsartan inhibits osteoclastogenesis by examining the major signaling
FIGURE 1 | Azilsartan inhibits RANKL-induced osteoclastogenesis in vitro. (A) The chemical structure of Azilsartan. (B) CCK-8 cytotoxicity assay was performed to assess the cytotoxic effect of Azilsartan in BMMs at 48 h and 96 h. (C) BMMs were treated with M-CSF (25 ng/ml), RANKL (100 ng/ml) and various concentrations of Azilsartan for 5 days. Then the cells were fixed with 4% PFA and stained for TRAP. (D) Quantitative analysis of TRAP positive multinucleated cells (nuclei >3) number and the area per well (%). (n = 3). (E) TRAP staining images showing BMMs were treated with 0.5 μM Azilsartan for indicated days during osteoclastogenesis. (F) Quantitative analysis of each group TRAP positive multinucleated cells in different time periods (n = 3). All data were obtained from three independent experiments and were shown as mean ± SD; *(p < 0.05, **p < 0.01, ***p < 0.005, ns, no significance, compared with the untreated control group).
FIGURE 2 | Azilsartan inhibits osteoclast resorption function and affects osteoclast-specific genes expression. (A) Representative images of osteoclast bone resorption on the hydroxyapatite surface; BMMs were treated with RANKL (100 ng/ml) for 3 days until small mature osteoclasts formed. Then, osteoclasts were reseeded and cultured with different concentrations of Azilsartan for another 3 days in hydroxyapatite-coated plates. (B) Quantitative analysis of the bone resorption area per well using the ImageJ software ($n = 3$). (C) The specific-genes expression of Nfatc1, Ctsk, Trap, c-Fos, Atp6v0d2, and Dc-stamp were determined by qPCR; BMMs were stimulated with RANKL and different concentrations of Azilsartan (0, 0.25, 0.5, and 1 μM) for 5 days ($n = 3$). Untreated cells were used as a control. (D) (Continued)
pathways affecting osteoclastogenesis, including NF-κB and MAPK. Western blot analyses indicated that both NF-κB and MAPK signaling were activated by RANKL stimulation. However, azilsartan treatment reduced p65 phosphorylation and IkBa phosphorylation, accompanied by the inhibition of IkBa degradation at 10–30 min (Figures 3C,D). Regarding the MAPK signaling pathway, the phosphorylation of P38, ERK, and JNK was significantly reduced after azilsartan treatment (Figures 3A,B), indicating a failure to activate MAPK signaling.

Furthermore, the expression of NFATc1/c-Fos, the essential transcriptional regulator involved in RANKL-induced osteoclastogenesis, was significantly suppressed on days 3 and 5 of osteoclastogenesis in BMMs treated with azilsartan (Figures 3E,F). Cathepsin K, which is considered a downstream protein of exercise-induced resorption function, was inhibited by azilsartan treatment (Figures 3E,F). In summary, our results showed that azilsartan suppressed osteoclastogenesis by inhibiting the NF-κB and MAPK pathways.

Azilsartan Inhibits RANKL-Induced ROS Production and Increases the Expression of Nrf2

ROS play a critical role in osteoclast formation (Lean et al., 2003), and previous studies have revealed that angiotensin II (Ang II) and aT1R are associated with intracellular ROS production (Benigni et al., 2010; Chao et al., 2018). Next, we examined the ROS level in osteoclast mitochondria using the MitoSOX Red probe. RANKL stimulation significantly increased the ROS level in mitochondria. However, azilsartan treatment resulted in a dose-dependent decrease in ROS levels in mitochondria (Figures 4A,B). Similarly, ROS levels in the cytoplasm were significantly reduced by azilsartan, as detected with the DCFH-DA fluorescence probe (Figures 4C,D).

Nrf2, a critical protein in the antioxidant stress system, regulates oxidative stress and ROS production by binding to antioxidant response elements (AREs) and promoting the transcription of downstream antioxidant and detoxification enzymes (Sun et al., 2015). In our study, the expression of Nrf2 and HO-1 was increased in the presence of azilsartan (Figures 4E,F). The expression of other antioxidant enzymes in the cellular antioxidant system, including catalase and SOD1, was increased at the mRNA levels after azilsartan treatment (Figure 4G). In summary, azilsartan exhibited potent antioxidant properties in osteoclasts.

Azilsartan Suppresses RANKL-Induced NF-κB/MAPK Signaling by Regulating Nrf2 in vitro

Next, we investigated the crosstalk among azilsartan, Nrf2, and osteoclastogenesis. A Nrf2-specific siRNA was transfected into BMMs. The efficiency of transfection was evaluated using Western blot analysis and quantitative PCR analysis, as shown in Figures 5A,B. Compared with the siCtrl group, a larger osteoclast area was observed in the siNrf2 group, and siNrf2 transfection diminished the inhibitory effect of azilsartan on osteoclast formation (Figures 5C,D). In addition, we further harvested the total cellular proteins from the aforementioned groups for Western blot analysis. Nrf2 silencing decreased the expression of antioxidant enzyme HO-1 and increased the expression of crucial osteoclast-associated transcription factors (NFATc1 and c-Fos) in osteoclastogenesis (Figures 5E,F). Surprisingly, azilsartan treatment had little effect on reversing siNrf2-mediated osteoclast formation and protein expression (Figures 5C,E), suggesting that Nrf2 likely acts as downstream of azilsartan.

Furthermore, we detected the levels of critical proteins involved in MAPK signaling to explore the underlying mechanisms by which azilsartan alters NF-κB and MAPK signaling. Nrf2 silencing using siNrf2 reversed the low levels of phosphorylated JNK, phosphorylated P38 and phosphorylated ERK in the azilsartan treatment group (Figures 5G,H). SiNrf2 transfection also reversed the repression of NF-κB signaling, as evidenced by increased levels of phosphorylated P65 and IkBa degradation (Figures 5G,I). Collectively, Nrf2 was identified as a downstream target of azilsartan that regulates MAPK and NF-κB signaling pathways in BMMs.

Azilsartan Administration Prevents OVX-Induced Bone Loss in vivo

We established an osteoporosis model in mice to explore the effect of azilsartan in vivo. No mouse death or other adverse events occurred during OVX surgery or azilsartan administration. Compared to the sham-operated group, the vehicle group showed significant bone loss. However, the azilsartan-treated group exhibited increased bone mass (Figure 6A). By measuring and comparing the bone parameters, we observed increases in the trabecular number (Tb. N), trabecular thickness (Tb. Th), and bone volume/tissue volume (BV/TV) and a decrease in trabecular separation (Tb. Sp) in the azilsartan-treated group compared with the vehicle group (Figure 6B). Bone histomorphometry results from H&E staining confirmed that azilsartan treatment prevented estrogen deficiency-induced bone loss (Figure 6C). Significant
trabecular destruction and bone loss were observed in the OVX groups. Azilsartan administration exerted a protective effect on bone in the low-dose groups and high-dose groups compared with the vehicle groups.

Likewise, TRAP staining showed that azilsartan treatment reduced the number of osteoclasts on each bone surface compared with that of the vehicle groups. The treatment also reduced the TRAP-positive cells/bone surfaces (Oc.S/BS%) ratio.
As azilsartan displayed good antioxidant activity in vitro, we next detected ROS levels using DHE fluorescent probes in frozen tibial sections. ROS levels within the bone marrow microenvironment were significantly increased after OVX surgery; however, azilsartan treatment reversed this trend (Figures 7A,B).

Furthermore, H&E staining of the lung, heart, spleen, liver, and kidney tissues indicated that azilsartan had no organ toxicity at the administered dose (Figure 7C). Blood biochemistry examinations of mouse serum showed no difference between the sham groups and azilsartan-treated groups (Supplementary Table S2; Supplementary Figure...
FIGURE 5 | Azilsartan suppresses RANKL-induced osteoclastogenesis in vitro via Nrf2. (A,B) RNAi of Nrf2 was generated by siRNA in BMMs. (C) BMMs were transfected with siNrf2 to reverse the inhibitory effect of Azilsartan in osteoclastogenesis. TRAP staining was performed to detect osteoclast formation. (D) Quantitative analysis of TRAP positive multinucleated cells (nuclei >3) number per well and the area per well (%) (n = 3). (E) Nrf2 silencing could upregulate the expression of NFATc1 and c-Fos, as evidenced by Western Blot analysis. (F) Quantitative analysis of the band intensity of Nrf2, HO-1, NFATc1, and c-Fos relative to GAPDH using the ImageJ software. (G) The phosphorylated P65, IκBα degeneration and phosphorylated P38/JNK/ERK were detected by Western blot. BMMs were transfected with siNrf2 for 48 h and then pre-treated with Azilsartan for 2 h before being stimulated by RANKL. The total proteins were harvested after 30 min of RANKL (100 ng/ml) stimulation. (H) Quantitative analysis of phosphorylated band intensity relative to total ERK/P38/JNK using the ImageJ software (n = 3). (I) Quantitative analysis of band intensity of p-P65, IκBα relative to P65, GAPDH (n = 3). All data were obtained from three independent experiments and were shown as mean ± SD. (* p < 0.05, ** p < 0.01, *** p < 0.005, ns, no significance).
Taken together, azilsartan administration ameliorates OVX-induced bone loss, possibly by inhibiting ROS production.

**DISCUSSION**

Osteoporosis, a common bone metabolic disease, has been a major threat to postmenopausal women and the aging population (Compston et al., 2019). Throughout the human lifetime, bone remodeling processes continuously occur. This biological process is mainly regulated by both osteoblasts and osteoclasts. However, excessive activation of osteoclasts in the presence of estrogen deficiency may lead to an imbalance in bone metabolism, resulting in osteoporosis (Boyle et al., 2003). Currently, clinically available drugs for osteoporosis, including hormone replacement, bisphosphonates, and denosumab, are effective but cause some adverse reactions, including gastrointestinal bleeding, atrial fibrillation, and increasing the risk of breast cancer (Shang, 2006; Knopp-Sihota et al., 2013). Therefore, novel alternative drugs that target osteoclasts are also required.
Based on accumulating evidence, ROS play a critical role in osteoclastogenesis (Lean et al., 2003; Agidigbi and Kim, 2019). RANKL induces ROS production in osteoclasts, and accordingly, the inhibition of ROS production inhibits osteoclastogenesis (Chen et al., 2019; Liu et al., 2019). Some drugs that inhibit ROS production in osteoclasts may be novel therapeutic approaches for osteoporosis (Wang et al., 2021). In our study, we first confirmed that azilsartan inhibits osteoclastogenesis by suppressing ROS production \textit{in vitro} and protects against OVX-induced osteoporosis \textit{in vivo}.

Ang II and its receptor (AT1R) have been reported to induce NADPH oxidase (NOX)-dependent oxidative stress, generating ROS in osteoclasts (Nguyen Dinh Cat et al., 2013; Zhang et al., 2019; Zhou et al., 2020). In our present study, we found that azilsartan, an AT1R blocker, suppressed intramitochondrial and intracellular ROS production in osteoclasts. Mice subjected to ovariectomy presented significantly increased ROS levels, while DHE fluorescence probes detected decreased ROS levels when animals were treated with azilsartan \textit{in vivo}. Meanwhile, elevated mRNA levels resulting from stimulation with RANKL, such as transcripts of osteoclastogenesis-related genes (\textit{c-Fos} and \textit{NFATc1}), genes encoding osteolysis-related enzymes (\textit{Trap} and \textit{Ctsk}), and genes involved osteoclast fusion (\textit{Atp6v0d2} and \textit{Dc-stamp}), were reversed by azilsartan treatment, suggesting impaired osteoclastogenesis and fusion failure. Besides, the results from micro-CT, H&E and TRAP staining confirmed that azilsartan prevented estrogen deficiency-induced bone loss and trabecular destruction \textit{in vivo}.

Previous studies have reported that Nrf2 is involved in regulating osteoclast formation and bone resorption function after its release from Kelch-like ECH-associated protein 1 (Keap1) and translocation into the nucleus, where it binds to AREs and ultimately activates downstream antioxidant enzymes to reduce ROS levels (Kanzaki et al., 2013). Keap1, a cytoplasmic actin-binding protein, encapsulates Nrf2 tethered in the cytoplasm and inhibits Nrf2 transactivation activity, causing the ubiquitination, and degradation of Nrf2 (Sun et al., 2015). Ni et al. found that schisandrin A increases the stability of Nrf2
and inhibits the ubiquitination and degradation of Nrf2 in osteoclasts. Intracellular ROS are the net effect of the balance between ROS generation and Nrf2-mediated clearance of ROS by the intracellular antioxidant system. Some antioxidants, such as pristimerin, chitosan, octyl itaconate, were reported to reduce ROS levels and inhibit osteoclast differentiation by activating Nrf2/HO-1 signaling (Chen et al., 2020; Ni et al., 2020; Qi et al., 2020). Nrf2 activation inhibits osteoclastogenesis, while inactivation of Nrf2 suppresses antioxidant enzyme expression and increases intracellular ROS levels in osteoclasts, subsequently promoting osteoclastogenesis (Kanzaki et al., 2013; Sun et al., 2020; Sánchez-de-Diego et al., 2021). As shown in our research, azilsartan activated the Nrf2-mediated intracellular antioxidant system, including HO-1, catalase and SOD1; reduced the level of intracellular ROS, and lead to a decline in osteoclastogenesis.

Several AT1R blockers seemingly activate Nrf2/HO-1 signaling and upregulate the expression of antioxidant enzymes, but further evidence is lacking in BMMs (Fujita et al., 2012; Matsumoto et al., 2014; Saber et al., 2019; Hou et al., 2021). Consistent with previous studies, our results showed that azilsartan activated Nrf2/HO-1 signaling. Further silencing of Nrf2 using siRNAs had little effect on reversing the changes induced by siNrf2, indicating that Nrf2 appears to be a downstream target of azilsartan in our study.

NF-κB and MAPK signaling are critical signaling cascades engaged in osteoclastogenesis. Phosphorylated NF-κB and MAPK signaling proteins activate the transcription factor NFATc1 and promote downstream genes transcription, including Ctsk, Trap, and Mmp9 (Boyle et al., 2003; Zhao et al., 2019). We observed that azilsartan treatment inhibited the degradation of IκBa and phosphorylation of P65 in BMMs. Furthermore, MAPK signaling, including phosphorylated P38, phosphorylated ERK, and phosphorylated JNK, was also significantly inhibited by azilsartan treatment in our study. These findings may reveal the molecular mechanism by which azilsartan inhibits osteoclastogenesis; however, the underlying mechanism requires further elucidation.

Recently, the interaction of Nrf2 and NF-κB/MAPK signaling in osteoclasts has been reported (Meng et al., 2021). The Nrf2 activator RTA-408 was reported to inhibit NF-κB signaling in osteoclasts, and STING and Rac-1 may be involved in this process (Sun et al., 2020). Nrf2 deficiency not only increased the activity of the NFATc1 protein and P38 MAP kinase but also increased ROS levels (Hyeon et al., 2013). In our present study, Nrf2 silencing facilitated NF-κB signaling pathway activation by increasing the phosphorylation of P65 and promoting the degradation of IκBa. Simultaneously, Nrf2 silencing reactivated MAPK signaling by facilitating the phosphorylation of P38/ERK/JNK following treatment with azilsartan. Taken together, Nrf2 may function as a potential downstream direct target of azilsartan to inhibit the NF-κB and MAPK signaling pathways.

Osteoporosis is regulated by osteoclasts and osteoblasts (Boyle et al., 2003). The limitation of the present study is that although we have explored the effect of azilsartan on osteoclasts, the effect on osteoblasts was not determined and requires further exploration. Second, we used mice with ovariectomy-induced osteoporosis as the study...
subjects; however, the cortical bone of mice does not contain the Harvard system and does not adequately reflect Harvard reconstruction. Therefore, we should choose a more suitable animal model in our future studies. Third, Nrf2 is mainly degraded by the ubiquitination process, and further studies are needed to determine whether azilsartan affects the ubiquitination-mediated degradation process.

CONCLUSION

In this study, we first found that azilsartan, a novel AT1R blocker, inhibits osteoclastogenesis in vitro and attenuates O VX-induced osteoporosis in vivo by suppressing ROS production. Mechanistically, azilsartan induced the expression of the antioxidant factor Nrf2, and inhibited the NF-κB/MAPK signaling pathways (Figure 8). Since azilsartan has been approved for clinical use, our findings indicate that azilsartan may be a promising therapeutic agent for the treatment of osteoporosis.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

REFERENCES

Abdelsaid, M., Coucha, M., and Ergul, A. (2014). Cerebrovasculoprotective Effects of Azilsartan Medoxomil in Diabetes. Transl Res. 164 (5), 424–432. doi:10.1016/j.trsl.2014.06.003
Agidigbi, T. S., and Kim, C. (2019). Reactive Oxygen Species in Osteoclast Differentiation and Possible Pharmaceutical Targets of ROS-Mediated Osteoclast Diseases. Int. J. Mol. Sci. 20 (1), 1. doi:10.3390/ijms20143576
Asaba, Y., Ito, M., Fumoto, T., Watanabe, K., Fukuura, R., Takeshita, S., et al. (2009). Activation of Renin-Angiotensin System Induces Osteoporosis Independently of Hypertension. J. Bone Miner Res. 24 (2), 241–250. doi:10.1359/jbmr.081006
Benigni, A., Cassis, P., and Remuzzi, G. (2010). Angiotensin II Revisited: New Roles in Inflammation, Immunology and Aging. EMBO Mol. Med. 2 (7), 247–257. doi:10.1002/emmm.201000080
Benigni, A., Corna, D., Zoja, C., Sonzogni, A., Latini, R., Salio, M., et al. (2009). Disruption of the Ang II Type 1 Receptor Promotes Longevity in Mice. J. Clin. Invest. 119 (3), 524–530. doi:10.1172/jci36703
Boutros, T., Chevet, E., and Metrakos, P. (2008). Mitogen-activated Protein (MAP) Kinase/MAP Kinase Phosphatase Regulation: Roles in Cell Growth, Death, and Cancer. Pharmcol Rev. 60 (3), 261–310. doi:10.1124/pr.110.001016
Boyle, W. J., Simonet, W. S., and Lacey, D. L. (2003). Osteoclast Differentiation and Activation. Nature 423 (6937), 337–342. doi:10.1038/nature01658
Bruzanati, A., and Baron, R. (2006). Molecular Regulation of Osteoclast Activity. Rev. Endocr. Metab. Disord. 7 (1-2), 123–139. doi:10.1007/s11154-006-9099-x
Chao, Y., Ye, P., Zhu, L., Kong, X., Qu, X., Zhang, J., et al. (2018). Low Shear Stress Induces Endothelial Reactive Oxygen Species via the AT1R/eNOS/NO Pathway. J. Cell Physiol 233 (2), 1384–1395. doi:10.1002/jcp.26016
Chen, K., Qin, P., Yuan, Y., Zheng, L., He, J., Wang, C., et al. (2019). Pseurotin A Inhibits Osteoclastogenesis and Prevents Ovariectomized-Induced Bone Loss by Suppressing Reactive Oxygen Species. Theranostics 9 (6), 1634–1650. doi:10.7150/thno.30206
Chen, R., Liu, G., Sun, X., Cao, X., He, W., Lin, X., et al. (2020). Chitosan Derived Nitrogen-Doped Carbon Dots Suppress Osteoclastic Osteolysis via Downregulating ROS. Nanoscale 12 (30), 16229–16244. doi:10.1039/ d8nr0248g
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P., Bonnelye, E., Paycha, F., et al. (2021). Bone Metastasis: Mechanisms, Therapies, and Biomarkers. Physiol. Rev. 101 (3), 797–855. doi:10.1152/physrev.00012.2019
Compton, J. E., McGllng, M. R., and Leslie, W. D. (2019). Osteoporosis. The Lancet 393 (10169), 364–376. doi:10.1016/s0140-6736(18)32112-3
de Cavanagh, E. M., Piotrowski, B., and Fraga, C. G. (2004). Concerted Action of the Renin-Angiotensin System, Mitochondria, and Antioxidant Defenses in Aging. Mol. Aspects Med. 25 (1-2), 27–36. doi:10.1016/j.mam.2004.02.006
Dong, Q., Li, Y., Chen, J., and Wang, N. (2021). Azilsartan Suppressed LPS-Induced Inflammation in U937 Macrophages through Suppressing Oxidative Stress and Inhibiting the TLR2/MyD88 Signal Pathway. ACS Omega 6 (1), 113–118. doi:10.1021/acsomega.0c03655
Fujita, H., Fujishima, H., Morii, T., Sakamoto, T., Komatsu, K., Hosoba, M., et al. (2012). Modulation of Renal Superoxide Dismutase by Telmisartan Therapy in CSB7R/6-Ins2(Akita) Diabetic Mice. Hypertens. Res. 35 (2), 213–220. doi:10.1038/hr.2011.176
Honma, M., Ikebuchi, Y., and Suzuki, H. (2021). RANKL as a Key Figure in Bridging between the Bone and Immune System: Its Physiological Functions and Potential as a Pharmacological Target. Pharmacol. Ther. 218, 107682. doi:10.1016/j.pharmthera.2020.107682
Hou, N., Li, L. R., Shi, Y. Y., Yuan, W. C., Zhao, G. J., Liu, X. W., et al. (2021). Azilsartan Ameliorates Ventricular Hypertrophy in Rats Suffering from Pressure Overload-Induced Cardiac Hypertrophy by Activating the Keap1-Nrf2 Signalling Pathway. J. Pharm. Pharmacol. 1, rgab097. doi:10.1093/jpp/rgab097

ETHICS STATEMENT

The animal study was reviewed and approved by the Ethics Committee of Lishui Hospital (Zhejiang University, Zhejiang, China).

AUTHOR CONTRIBUTIONS

DH and CL designed the experiments. BP, JF, YZ, and KN performed the experiments and acquired the data. BP, WP, YL, and JG analyzed the data. HL and LZ supervised the project and BP wrote the article. All authors contributed to the article and approved the submitted version.

FUNDING

The Key Research and Development Project of Zhejiang Province (2021C03194) Zhejiang Province Scientific Project of Health and Medicine (2021KY416).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.774709/full#supplementary-material
Qi, D., Liu, H., Sun, X., Luo, D., Zhu, M., Tao, T., et al. (2020). Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Osteoporosis-Induced Bone Loss. Front. Pharmacol. 11, 621110. doi:10.3389/fphar.2020.621110

Raiz, L. (2005). Pathogenesis of Osteoporosis: Concepts, Conflicts, and Prospects. J. Clin. Invest. 115 (12), 3318–3325. doi:10.1172/jci27071

Rodan, G. A., and Martin, T. J. (2000). Therapeutic Approaches to Bone Diseases. Science 289 (5488), 1508–1514. doi:10.1126/science.289.5484.1508

Saber, S., Khalil, R. M., Abdo, W. S., Nassif, D., and El-Ahwany, E. (2019). Olmesartan Ameliorates Chemically-Induced Ulcerative Colitis in Rats via Modulating NFκB and Nrf-2/HO-1 Signaling Crosstalk. Toxicol. Appl. Pharmacol. 364, 120–132. doi:10.1016/j.taap.2018.12.020

Sánchez-de-Diego, C., Pedraza, L., Pimenta-Lopes, C., Martínez-Martínez, A., Dahdah, N., Valer, J. A., et al. (2021). Nrf2 Function in Osteocytes Is Required for Bone Homeostasis and Drives Osteocyte Gene Expression. Redox Biol. 40, 101845. doi:10.1016/j.redox.2020.101845

Sasaki, H., Yamamoto, H., Tominaga, K., Masuda, K., Kawai, T., Teshima-Kondo, S., et al. (2009). Receptor Activator of Nuclear Factor-kappaB Ligand-Induced Mouse Osteoclast Differentiation Is Associated with Switching between NADPH Oxidase Homologues. Free Radic. Biol. Med. 47 (2), 189–199. doi:10.1016/j.freeradbiomed.2009.04.025

Shang, Y. (2006). Molecular Mechanisms of Osterogen and SERMs in Endometrial Carcinogenesis. Nat. Rev. Cancer 6 (5), 360–368. doi:10.1038/nrc1879

Sukumaran, V., Tsuchimochi, H., Satumi, E., Shirai, M., and Pearson, J. T. (2017). Azilsartan Ameliorates Diabetic Cardiomyopathy in Young Db/db Mice through the Mode of ACTION 2-ANG 1-7/Mas Receptor cascade. Biochem. Pharmacol. 144, 90–99. doi:10.1016/j.bcp.2017.07.022

Sun, X., Xie, Z., Hu, B., Zhang, B., Ma, Y., Pan, X., et al. (2020). The Nfr2 Activator RTA-408 Attenuates Osteoclastogenesis by Inhibiting STING Dependent NF-κB Signaling. Redox Biol. 28, 101309. doi:10.1016/j.redox.2019.101309

Sun, Y. X., Xu, A. H., Yang, Y., and Li, J. (2015). Role of Nrf2 in Bone Metabolism. J. Biomed. Sci. 22, 101. doi:10.1007/s12929-015-0212-5

Tan, E. M., Li, L., Indran, I. R., Chew, N., and Yong, E. L. (2017). TRAF6 Mediates Suppression of Osteoclastogenesis and Prevention of Ovariectomy-Induced Bone Loss by a Novel Prenylflavonoid. J. Bone Miner Res. 32 (4), 846–860. doi:10.1002/jbmr.3031

Walsh, M. C., Lee, J., and Choi, Y. (2015). Tumor Necrosis Factor Receptor-Associated Factor 6 (TRAF6) Regulation of Development, Function, and Homeostasis of the Immune System. Immunol. Rev. 266 (1), 72–92. doi:10.1111/imr.12302

Wang, S., Ma, Q., Xie, Z., Shen, Y., Zheng, B., Jiang, C., et al. (2021). An Antioxidant Suscepterine Inhibits Osteoclastogenesis via Blocking IP3K/ TRAP6 and Counteracts OXV- Induced Osteoporosis in Mice. J. Bone Miner Res. 36, 1850–1865. doi:10.1002/jbmr.4328

Xu, S., Cao, X., Yu, Z., He, W., Pang, Y., Lin, W., et al. (2021). Nicorandil Inhibits Osteoclast Formation Base on NF-κB and P-38 MAPK Signaling Pathways and Relieves Ovariectomy-Induced Bone Loss. Front. Pharmacol. 12, 726361. doi:10.3389/fphar.2021.726361

Yamashita, T., Yao, Z., Li, F., Zhang, Q., Badell, I. R., Schwarz, E. M., et al. (2007). NF-kappaB P50 and P52 Regulate Receptor Activator of NF-kappaB Ligand (RANKL) and Tumor Necrosis Factor-Induced Osteoclast Precursor Differentiation by Activating C-Fox and NFATc1. J. Biol. Chem. 282 (25), 18245–18253. doi:10.1074/jbc.M10701200

Yang, W., Lu, X., Zhang, T., Han, W., Li, J., He, W., et al. (2021). TAZ Inhibits Osteoclastogenesis by Attenuating TAK1/NF-κB Signaling. Bone Res. 9 (1), 33. doi:10.1089/s41413-021-00151-3

Zhang, F., Dong, Z., Gao, S., Chen, G., and Liu, D. (2019). ATIR-Mediated Apoptosis of Bone Marrow Mesenchymal Stem Cells Is Associated with mtROS Production and mtDNA Reduction. Oxid Med. Cell Longev 2019, 4608165. doi:10.1155/2019/4608165

Zhao, X., Ning, L., Xie, Z., Ju, Z., Li, X., Wan, X., et al. (2019). The Novel P38 Inhibitor, Pamapimod, Inhibits Osteoclastogenesis in Ld37 Counteracts Estrogen-dependent Bone Loss in Mice. J. Bone Miner Res. 34 (5), 911–922. doi:10.1002/jbmr.3655

Zhou, Z., Wang, C., Xu, Y., Wang, X., Jia, B., Yu, T., et al. (2021). Effects of the Local Bone Renin-Angiotensin System on Titanium-Particle-Induced Periimplant Osteolysis. Front. Pharmacol. 12, 684375. doi:10.3389/fphar.2021.684375
Zheng, L., Gao, J., Jin, K., Chen, Z., Yu, W., Zhu, K., et al. (2019). Macrophage Migration Inhibitory Factor (MIF) Inhibitor 4-IPP Suppresses Osteoclast Formation and Promotes Osteoblast Differentiation through the Inhibition of the NF-κb Signaling Pathway. *Faseb J* **33**(6), 7677–7683. doi:10.1096/fj.201802364RR

Zhou, L., Zhang, S., Bolor-Erdene, E., Wang, L., Tian, D., and Mei, Y. (2020). NAMPT/ SIRT1 Attenuate Ang II-Induced Vascular Remodeling and Vulnerability to Hypertension by Inhibiting the ROS/MAPK Pathway. *Oxid Med. Cell Longev* 2020, 1974265. doi:10.1155/2020/1974265

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2021 Pan, Zheng, Fang, Lin, Lai, Gao, Pan, Zhang, Ni, Lou and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*